Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation
Recommend 3 Positive 2 Negative 0 |
||||
|
||||
|
TRANSCENTA-B (06628.HK) announced that its partner Inhibrx Biosciences, Inc. (INBX.US) recently reported positive updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). Inhibrx also announced the submission of a Biologics License Application (BLA) to the FDA for ozekibart in conventional chondrosarcoma in April 2026. Transcenta holds the exclusive rights to develop and commercialize ozekibart (INBRX-109) in mainland China, Hong Kong SAR, Macau SAR, and Taiwan region under a license agreement executed through HJB, a wholly owned subsidiary of the Company. In light of these positive developments for ozekibart, Transcenta is actively evaluating its plans in the Greater China region. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
